The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever
These studies demonstrate that INO-4500 can provide short- and long-term protection in NHPs from lethal LASV challenge.
Authors
- Friederike Feldmann (ORCID: https://orcid.org/0000-0002-1363-1077)
- Patrick W. Hanley (ORCID: https://orcid.org/0000-0003-2300-1818)
- Laurent Humeau
- Kyle Rosenke (ORCID: https://orcid.org/0000-0001-8101-4348)
- Jingjing Jiang (ORCID: https://orcid.org/0000-0003-1886-2613)
- Nicole Josleyn
- Jesse Steffens
- Sean Vantongeren
- Heinz Feldmann (ORCID: https://orcid.org/0000-0001-9448-8227)
- Trevor R.F. Smith (ORCID: https://orcid.org/0000-0002-0671-2565)
- Jamie Lovaglio (ORCID: https://orcid.org/0000-0002-7567-446X)
- Kate E. Broderick (ORCID: https://orcid.org/0000-0003-2682-2363)
- Jean Boyer (ORCID: https://orcid.org/0000-0001-8699-0532)
- Stephanie Ramos (ORCID: https://orcid.org/0000-0002-5326-4937)
- Eric R. Wilkinson
- Kathleen A. Cashman
- Paul R. Facemire (ORCID: https://orcid.org/0000-0003-2607-8431)
- Viviane M. Andrade (ORCID: https://orcid.org/0000-0002-5056-298X)
- Connie S. Schmaljohn (ORCID: https://orcid.org/0000-0002-8834-0784)
- Jay Wells
- Aditya Patel
- Kimberly A. White
- Ginger Lynn
Institutions
- National Institutes of Health (US)
- United States Army Medical Research Institute of Infectious Diseases (US)
- National Institute of Allergy and Infectious Diseases (US)
- Inovio Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1038/s43856-024-00684-8
- Citations
- 9
- Primary Topic
- Viral Infections and Outbreaks Research
- Type
- article
- Field-Weighted Citation Impact
- 3.50
Funders
- INOVIO Pharmaceuticals
- Coalition for Epidemic Preparedness Innovations
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases